|
The One Big Beautiful Bill Act (OBBBA), signed into law by US President Trump on July 4, 2025, includes provisions that introduce a 1% excise tax on certain outbound remittances by non-US citizens, reduced from an initial proposal of 5%. This has generated discussion about its effects on the Indian pharma industry.
Indian pharma industry experts have provided an overview based on available sources.
Vikas Nim, pharma industry specialist explains that India’s pharma sector, the world’s third-largest by volume and a major exporter of generics (USD 20-25 billion annually to the US), relies on NRI investments for R&D and manufacturing. The remittance tax could marginally reduce NRI capital inflows if costs rise, but this is minor compared to OBBBA’s broader effects: USD 1-1.2 trillion in Medicaid cuts over a decade, work requirements, and co-pays, potentially leading to 10-12 million uninsured Americans. This may decrease demand for affordable generics, as uninsured patients delay care, projecting a 5-10% US revenue drop for Indian exporters over the next decade.
A weakened rupee (if any) would raise costs for imported raw materials/APIs. India imports 60-70% from China, but OBBBA’s protectionist trade policies could increase tariffs, further increasing expenses.
Experts recommend that Indian companies should enhance pricing transparency, launch PR campaigns emphasizing affordable generics, diversify to markets like the EU, Africa, or Latin America and collaborate with bodies like the Indian Pharmaceutical Alliance (IP Alliance) to influence US policy. Hedging forex and leveraging global networks are key to mitigating costs.
Talking about the economic effects on Diaspora and India, Archana Arya, NIPER MBA Alumni, “For NRIs (e.g., tech workers, professionals), the tax adds costs to family support or investments back home, potentially discouraging smaller, cash-based sends. In India, reduced remittances could exert mild downward pressure on the rupee but estimates of Rs. 1-1.5 per USD weakening are unsubstantiated and likely overstated.”
|